• Aprogen Biologics completed a third-party private placement of 12,706,481 registered common shares.
• Gross proceeds totaled KRW 20 billion.
• Cash was received on Sept. 23, 2026.
• The financing was first authorized by the board on Sept. 3, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprogen Biologics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260923800575), on September 23, 2026, and is solely responsible for the information contained therein.